S" and the partnership between self-reported adherence and efavirenz blood levels

20. Masquelier B, Pereira E, Peytavin G, Descamps D, Reynes J, Verdon R, Fleury H, Garraffo R, Chene G, Raffi F, et al. Intermittent viremia during first-line, protease inhibitors-containing therapy: significance and relationship with drug resistance. J Clin Virol. 2005;33(1):75?. 21. Mira JA, Macias J, Nogales C, Fernandez-Rivera J, Garcia-Garcia JA, Ramos A, Pineda JA. Transient rebounds of low-level viraemia among HIV-infected patients under HAART are not associated with virological or immunological failure. Antivir Ther. 2002;7(4):251?. 22. Sklar PA, Ward DJ, Baker RK, Wood KC, Gafoor Z, Alzola CF, Moorman AC, Holmberg SD. Prevalence and clinical correlates of HIV viremia (`blips') in patients with previous suppression below the limits of quantification. AIDS. 2002;16(15):2035?1. 23. Raboud JM, Rae S, Woods R, Harris M, Montaner JS. Consecutive rebounds in plasma viral load are associated with virological failure at 52 weeks among HIV-infected patients. AIDS. 2002;16(12):1627?2. 24. Martinez V, Marcelin AG, Morini JP, Deleuze J, Krivine A, Gorin I, Yerly S, Perrin L, Peytavin G, Calvez V, et al. HIV-1 intermittent viraemia in title= j.1369-6513.1999.00027.x patients treated by non-nucleoside reverse transcriptase inhibitor-based regimen. Garcia-Gasco P, Maida I, Blanco F, Barreiro P, Martin-Carbonero L, Vispo E, Gonzalez-Lahoz J, Een what we profess and what we are" (Monk, 1955, p. 60). Gulliver Soriano V. 17. Greub G, Cozzi-Lepri A, Ledergerber B, Staszewski S, Perrin L, Miller V, Francioli P, Furrer H, Battegay M, Vernazza P, et al. Intermittent and sustained low-level HIV viral rebound in patients getting potent antiretroviral therapy. AIDS. 2002;16(14):1967?.S stedt et al. BMC Infectious Ailments (2016) 16:Page 9 of18. Easterbrook PJ, Ives N, Waters A, Mullen J, O'Shea S, Peters B, Gazzard BG. The natural history and clinical significance of intermittent viraemia in sufferers with initial viral suppression to